Skip to main content

Compare Stocks

Date Range: 

 Merit Medical SystemsHaemoneticsNuVasiveCantel MedicalAtriCure
SymbolNASDAQ:MMSINYSE:HAENASDAQ:NUVANYSE:CMDNASDAQ:ATRC
Price Information
Current Price$59.68$51.81$68.59$83.93$70.46
52 Week RangeBuyBuyHoldHoldBuy
MarketRank™
Overall Score1.71.91.21.31.7
Analysis Score2.43.31.21.03.5
Community Score2.72.22.72.42.9
Dividend Score0.00.00.00.00.0
Ownership Score1.71.70.01.71.7
Earnings & Valuation Score1.92.51.91.30.6
Analyst Ratings
Consensus RecommendationBuyBuyHoldHoldBuy
Consensus Price Target$67.00$115.40$68.43$71.50$79.14
% Upside from Price Target12.27% upside122.74% upside-0.24% downside-14.81% downside12.32% upside
Trade Information
Market Cap$3.34 billion$2.63 billion$3.54 billion$3.74 billion$3.22 billion
Beta1.210.561.361.541.13
Average Volume275,050704,220712,722511,980401,790
Sales & Book Value
Annual Revenue$994.85 million$988.48 million$1.17 billion$1.02 billion$230.81 million
Price / Sales3.362.663.033.6813.93
Cashflow$3.59 per share$2.29 per share$6.72 per share$3.70 per shareN/A
Price / Cash16.6422.5910.2022.69N/A
Book Value$17.21 per share$11.67 per share$17.58 per share$17.31 per share$6.25 per share
Price / Book3.474.443.904.8511.27
Profitability
Net Income$5.45 million$76.53 million$65.23 million$13.71 million$-35,190,000.00
EPS$1.46$3.31$2.47$1.65($1.07)
Trailing P/E RatioN/A25.03N/A99.92N/A
Forward P/E Ratio32.0914.7629.3128.84N/A
P/E Growth2.405.171.791.57N/A
Net Margins-3.05%11.76%-0.84%3.38%-21.74%
Return on Equity (ROE)9.02%22.85%8.00%11.19%-14.83%
Return on Assets (ROA)4.91%10.40%3.06%4.10%-7.77%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/A-25.00%N/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.37%0.44%0.85%1.28%0.15%
Current Ratio2.34%2.25%1.85%3.13%6.62%
Quick Ratio1.21%1.34%1.48%2.31%5.85%
Ownership Information
Institutional Ownership Percentage99.47%96.22%N/A95.01%94.70%
Insider Ownership Percentage4.70%1.63%0.89%10.70%5.80%
Miscellaneous
Employees5,9893,0042,7003,669750
Shares Outstanding56.00 million50.82 million51.65 million44.51 million45.63 million
Next Earnings Date8/4/2021 (Estimated)N/A8/3/2021 (Estimated)6/3/2021 (Estimated)7/27/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
AtriCure, Inc. (NASDAQ:ATRC) Director Scott William Drake Sells 4,631 SharesAtriCure, Inc. (NASDAQ:ATRC) Director Scott William Drake Sells 4,631 Shares
americanbankingnews.com - May 11 at 12:11 PM
Scott William Drake Sells 38,641 Shares of AtriCure, Inc. (NASDAQ:ATRC) StockScott William Drake Sells 38,641 Shares of AtriCure, Inc. (NASDAQ:ATRC) Stock
americanbankingnews.com - May 11 at 12:11 PM
AtriCure (NASDAQ:ATRC) Shares Gap Down to $77.67AtriCure (NASDAQ:ATRC) Shares Gap Down to $77.67
americanbankingnews.com - May 11 at 10:56 AM
Business Outlook for Peripheral Interventions Market 2021 by Abbott Laboratories, AtriCure Inc., AngioDynamics, Inc – Clark County Blog - Clark County BlogBusiness Outlook for Peripheral Interventions Market 2021 by Abbott Laboratories, AtriCure Inc., AngioDynamics, Inc – Clark County Blog - Clark County Blog
clarkcountyblog.com - May 11 at 7:50 AM
Form 4 AtriCure, Inc. For: May 05 Filed by: Lanning Mark R - StreetInsider.comForm 4 AtriCure, Inc. For: May 05 Filed by: Lanning Mark R - StreetInsider.com
streetinsider.com - May 7 at 6:41 PM
AtriCure (NASDAQ:ATRC) Hits New 12-Month High at $80.20AtriCure (NASDAQ:ATRC) Hits New 12-Month High at $80.20
americanbankingnews.com - May 7 at 12:44 PM
Form 4 AtriCure, Inc. For: May 03 Filed by: WEHRWEIN SVEN - StreetInsider.comForm 4 AtriCure, Inc. For: May 03 Filed by: WEHRWEIN SVEN - StreetInsider.com
streetinsider.com - May 5 at 2:05 PM
Insider Selling: AtriCure, Inc. (NASDAQ:ATRC) Director Sells 10,000 Shares of StockInsider Selling: AtriCure, Inc. (NASDAQ:ATRC) Director Sells 10,000 Shares of Stock
americanbankingnews.com - May 5 at 11:14 AM
AtriCure (NASDAQ:ATRC) PT Raised to $102.00AtriCure (NASDAQ:ATRC) PT Raised to $102.00
americanbankingnews.com - May 4 at 11:12 AM
AtriCure (NASDAQ:ATRC) Given New $75.00 Price Target at OppenheimerAtriCure (NASDAQ:ATRC) Given New $75.00 Price Target at Oppenheimer
americanbankingnews.com - May 4 at 10:36 AM
Global Atrial Fibrillation Drugs Market 2025: Top Key Players AtriCure Inc., CardioFocus Inc. and others – FLA News - FLA NewsGlobal Atrial Fibrillation Drugs Market 2025: Top Key Players AtriCure Inc., CardioFocus Inc. and others – FLA News - FLA News
flanewsonline.com - May 4 at 10:35 AM
AtriCure (NASDAQ:ATRC) Releases FY 2021 Earnings GuidanceAtriCure (NASDAQ:ATRC) Releases FY 2021 Earnings Guidance
americanbankingnews.com - May 4 at 9:22 AM
AtriCure (NASDAQ:ATRC) Price Target Raised to $81.00 at Needham & Company LLCAtriCure (NASDAQ:ATRC) Price Target Raised to $81.00 at Needham & Company LLC
americanbankingnews.com - May 4 at 8:46 AM
AtriCure, Inc. (NASDAQ:ATRC) Expected to Post Earnings of -$0.33 Per ShareAtriCure, Inc. (NASDAQ:ATRC) Expected to Post Earnings of -$0.33 Per Share
americanbankingnews.com - May 3 at 6:46 PM
AtriCures EPi-Sense system approved by US FDA for treatment of long-standing persistent AF - Cardiac Rhythm NewsAtriCure's EPi-Sense system approved by US FDA for treatment of long-standing persistent AF - Cardiac Rhythm News
cardiacrhythmnews.com - May 1 at 8:25 AM
Is AtriCure Inc. (ATRC) a Leader in the Healthcare Sector? - InvestorsObserverIs AtriCure Inc. (ATRC) a Leader in the Healthcare Sector? - InvestorsObserver
investorsobserver.com - May 1 at 12:56 AM
AtriCure (NASDAQ:ATRC) Lowered to "Hold" at Zacks Investment ResearchAtriCure (NASDAQ:ATRC) Lowered to "Hold" at Zacks Investment Research
marketbeat.com - April 30 at 4:40 PM
The Wait Is Over — FDA Approves Device for Long-Standing Persistent Afib - Medical Device and Diagnostics IndustryThe Wait Is Over — FDA Approves Device for Long-Standing Persistent Afib - Medical Device and Diagnostics Industry
mddionline.com - April 30 at 9:56 AM
AtriCure (ATRC) Soars 8.8%: Is Further Upside Left in the Stock? - Yahoo FinanceAtriCure (ATRC) Soars 8.8%: Is Further Upside Left in the Stock? - Yahoo Finance
finance.yahoo.com - April 30 at 9:56 AM
Atricure scores win at FDA with atrial fibrillation solution - BioWorld OnlineAtricure scores win at FDA with atrial fibrillation solution - BioWorld Online
bioworld.com - April 30 at 9:56 AM
Can You Imagine How Elated AtriCures (NASDAQ:ATRC) Shareholders Feel About Its 427% Share Price Gain?Can You Imagine How Elated AtriCure's (NASDAQ:ATRC) Shareholders Feel About Its 427% Share Price Gain?
finance.yahoo.com - April 30 at 9:56 AM
AtriCure (ATRC) Soars 8.8%: Is Further Upside Left in the Stock?AtriCure (ATRC) Soars 8.8%: Is Further Upside Left in the Stock?
finance.yahoo.com - April 30 at 9:56 AM
AtriCure Inc. (ATRC) PT Raised to $91 at Needham & Company on FDA Approval - StreetInsider.comAtriCure Inc. (ATRC) PT Raised to $91 at Needham & Company on FDA Approval - StreetInsider.com
streetinsider.com - April 29 at 7:23 PM
AtriCure (NASDAQ:ATRC) PT Raised to $85.00AtriCure (NASDAQ:ATRC) PT Raised to $85.00
americanbankingnews.com - April 29 at 6:48 PM
Is AtriCure Inc. (ATRC) a Smart Choice in Medical Instruments & Supplies Thursday? - InvestorsObserverIs AtriCure Inc. (ATRC) a Smart Choice in Medical Instruments & Supplies Thursday? - InvestorsObserver
investorsobserver.com - April 29 at 2:22 PM
Stocks Showing Rising Market Leadership: Atricure Earns 81 RS Rating - Investors Business DailyStocks Showing Rising Market Leadership: Atricure Earns 81 RS Rating - Investor's Business Daily
investors.com - April 29 at 2:22 PM
DateCompanyBrokerageAction
5/6/2021Merit Medical SystemsRaymond JamesBoost Price Target
5/6/2021Merit Medical SystemsNeedham & Company LLCBoost Price Target
4/30/2021Merit Medical SystemsBarrington ResearchBoost Price Target
2/26/2021Merit Medical SystemsCanaccord GenuityBoost Price Target
11/11/2020Merit Medical SystemsWells Fargo & CompanyBoost Price Target
11/11/2020Merit Medical SystemsOppenheimerBoost Price Target
10/29/2020Merit Medical SystemsSidotiBoost Price Target
10/29/2020Merit Medical SystemsPiper SandlerBoost Price Target
4/26/2021HaemoneticsMorgan StanleyReiterated Rating
4/19/2021HaemoneticsCJS SecuritiesDowngrade
1/21/2021HaemoneticsJMP SecuritiesBoost Price Target
4/27/2021NuVasiveTruistBoost Price Target
3/31/2021NuVasiveCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/16/2020NuVasiveSmith Barney CitigroupUpgrade
10/30/2020NuVasiveBTIG ResearchDowngrade
8/19/2020Cantel MedicalBank of AmericaInitiated Coverage
4/29/2021AtriCureSVB LeerinkReiterated Rating
7/29/2020AtriCureJPMorgan Chase & Co.Boost Price Target
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.